GLP-1 receptor agonists (e.g., semaglutide , tirzepatide ) are FDA-approved for type 2 diabetes and/or obesity/weight management
E66.3 for overweight) An ICD-10 code for the qualifying tier condition, where applicable The prescribing clinician's National Provider Identifier (NPI) and a statement that they are not on the CMS Preclusion List Documentation that the medication will be used alongside structured nutrition and physical activity Date of last clinical visit with the prescribing provider The specific medication being requested (Wegovy, Zepbound, or Foundayo) with dose and quantity Some Part D plans add requirements such as documented prior lifestyle intervention attempts, weight history over the past 24 months, or signed patient acknowledgment of the long-term nature of treatment
With this, you can accomplish stability of formulation
Lab results showing relevant biomarkers like A1C, fasting glucose, and lipid panels
The criteria for selecting the right needle has three primary considerations--gauge, length, and use
This process helps keep at-home support connected to the same oversight standards clients expect from our mobile IV visits
